PEDIATRICS Vol. 80 No. 4 October 1987, pp. 590-592
This Article
Right arrow Full Text (PDF)
Right arrow P3Rs: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when P3Rs are posted
Right arrow Alert me if a correction is posted
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by GRANOFF, D. M.
Right arrow Articles by OSTERHOLM, M. T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by GRANOFF, D. M.
Right arrow Articles by OSTERHOLM, M. T.

Safety and Efficacy of Haemophilus influenzae Type b Polysaccharide Vaccine

DAN M. GRANOFF MD1 and MICHAEL T. OSTERHOLM PHD, MPH2

1 Edward Mallinckrodt Department of Pediatrics, Washington University School of Medicine and Division of Infectious Diseases, Children's Hospital, St Louis
2 Acute Disease Epidemiology Section, Minnesota Department of Health, Minneapolis

Haemophilus influenzae type b vaccine was licensed in the United States in the spring of 1985. Prior to licensure, extensive data had accumulated, indicating that this vaccine was safe and was immunogenic in children >18 to 23 months of age. Furthermore, in a large efficacy trial conducted in Finland, the vaccine also was found to be approximately 80% protective in preventing invasive type b Haemophilus disease in children 24 to 35 months of age (95% confidence interval 8, 95).1,2 Unfortunately, it was ineffective in children <18 months of age, the group most susceptible to Haemophilus disease, and it was of uncertain efficacy in those 18 to 23 months of age.